Cigna Group (CI) will begin covering RhinAer, a minimally invasive treatment for chronic rhinitis, starting September 15, 2025. This decision will grant access to over 15 million members across the U.S., marking a significant shift as RhinAer moves off the list of experimental treatments.
RhinAer uses temperature-controlled radiofrequency technology to target the posterior nasal nerve and has already benefited more than 50,000 patients. The treatment is incisionless and can be performed with local anesthesia during a routine office visit, as substantiated by more than 20 clinical studies and three years of outcome data.
In 2024, Cigna delivered over 8 million prescriptions to more than a million patients. Cigna’s stock has increased by 0.3% over the past year, contrasting with a 29.7% decline in the medical industry.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
